{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-076108","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.293144+00:00","generated_at":"2026-05-31T06:14:01.946924+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LYMPHIR added to NCCN Guidelines for CTCL treatment","bullets":["NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.","LYMPHIR targets IL-2 receptor on malignant T-cells; FDA approved based on Phase 3 study results.","CEO says NCCN inclusion could aid physician adoption and ease reimbursement, potentially expanding CMS coverage.","Citius Pharma (CTXR) and Citius Oncology (CTOR) jointly announced the guideline addition on Sep 5, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-076108","json":"https://secwatch.observer/filing/0001213900-24-076108.json","markdown":"https://secwatch.observer/filing/0001213900-24-076108.md","text":"https://secwatch.observer/filing/0001213900-24-076108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024076108/0001213900-24-076108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024076108/ea0213639-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:14:01.946924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}